Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Zevra Therapeutics (ZVRA) Amortization - Deferred Charges (2016 - 2021)

Historic Amortization - Deferred Charges for Zevra Therapeutics (ZVRA) over the last 7 years, with Q1 2021 value amounting to $150000.0.

  • Zevra Therapeutics' Amortization - Deferred Charges fell 7373.03% to $150000.0 in Q1 2021 from the same period last year, while for Dec 2021 it was $150000.0, marking a year-over-year decrease of 9349.24%. This contributed to the annual value of $150000.0 for FY2021, which is 9349.24% down from last year.
  • Zevra Therapeutics' Amortization - Deferred Charges amounted to $150000.0 in Q1 2021, which was down 7373.03% from $582000.0 recorded in Q4 2020.
  • Zevra Therapeutics' 5-year Amortization - Deferred Charges high stood at $675000.0 for Q4 2019, and its period low was $150000.0 during Q1 2021.
  • Over the past 4 years, Zevra Therapeutics' median Amortization - Deferred Charges value was $390000.0 (recorded in 2018), while the average stood at $440692.3.
  • As far as peak fluctuations go, Zevra Therapeutics' Amortization - Deferred Charges skyrocketed by 8819.67% in 2020, and later crashed by 7373.03% in 2021.
  • Zevra Therapeutics' Amortization - Deferred Charges (Quarter) stood at $512000.0 in 2018, then skyrocketed by 31.84% to $675000.0 in 2019, then decreased by 13.78% to $582000.0 in 2020, then plummeted by 74.23% to $150000.0 in 2021.
  • Its Amortization - Deferred Charges stands at $150000.0 for Q1 2021, versus $582000.0 for Q4 2020 and $578000.0 for Q3 2020.